Insmed's stock soared 5.38% during intraday trading on Thursday, driven by the company's fourth-quarter financial results and positive business outlook.

The biopharmaceutical company reported quarterly sales of $263.8 million, significantly beating analyst estimates of $221.9 million and representing a 152.6% increase over the same period last year. Despite reporting a wider net loss of $1.54 per share compared to estimates of $1.12, investors focused on the substantial revenue growth and forward-looking guidance.

Insmed provided optimistic 2026 forecasts, expecting BRINSUPRI revenues to exceed $1 billion and reiterating ARIKAYCE revenue guidance of $450-$470 million. The company also announced regulatory progress, including European Commission approval for BRINSUPRI for non-cystic fibrosis bronchiectasis and expectations for regulatory decisions in the UK and Japan in 2026. Additionally, the FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension, with a Phase 3 study planned for the first half of 2026.